The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus

QR Code

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus

Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the loss of glycemic control. Recent studies have shown significant inflammation and disturbed bile acid homeostasis, associated with T1DM. Bile acids are endogenously produced as a result of cholesterol catabolism in the live...

Full description

Bibliographic Details
Main Authors:	Woodhams, L., Al-Salami, Hani
Format:	Journal Article
Published:	2017
Online Access:	http://hdl.handle.net/20.500.11937/53549

Similar Items

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
by: Mathavan, Sangeetha
Published: (2017)

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Reducing microvascular complications in type 2 diabetes mellitus: new approaches and pharmacists’ role
by: Woodhams, Louise Maree
Published: (2023)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics
by: Al-Salami, Hani, et al.
Published: (2008)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes
by: Mathavan, Sangeetha, et al.
Published: (2015)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

The role of diabetes-associated autoantibodies in confirming the diagnosis of type 1 diabetes mellitus in children and adolescents
by: Gazali, Ahmad Mahfuz
Published: (2023)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable ß-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
by: Mooranian, A., et al.
Published: (2015)

New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic ß-cell delivery: bile acids support cell energy-generating mechanisms
by: Mooranian, A., et al.
Published: (2017)

Literature Review on Herbs that Treat Type 2 Diabetes Mellitus (T2DM)
by: Tan, Yi Huey
Published: (2015)

Designing anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: Morphology, bioenergetics and cytokine analysis.
by: Mooranian, A., et al.
Published: (2016)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic ?-Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Bromocriptine for type 2 diabetes mellitus
by: Ooi, Cheow Peng, et al.
Published: (2013)

Oral health of children with Type 1 diabetes mellitus: systematic review
by: Ismail, Ahmad Faisal
Published: (2014)

Systematic review of exercise interventions for children with Type 1 diabetes mellitus
by: Cooper, Y., et al.
Published: (2011)

Quality of life in children and adolescents with type 1 diabetes mellitus in HUSM
by: Nordin, Siti Nuraihan
Published: (2017)

Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of ß-cells
by: Mooranian, Armin, et al.
Published: (2016)

Novel multicompartmental bile acid-based microcapsules for pancreatic β-cell transplantation
by: Mooranian, A., et al.
Published: (2015)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)